BTIG keeps a Buy rating on Mersana Therapeutics (MRSN) with a $6 price target after the company presented data for Emi-Le from the Phase I study in solid tumors. The firm views the data favorably with a 23% overall response rate and a “differentiated” safety profile, exceeding its base case and approaching its bull case scenario. BTIG says the selloff in the stock post the data is overdone.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSN:
- Mersana Therapeutics Gains Fast Track for Emi-Le
- Mersana Therapeutics: FDA grants additional Fast Track designation to XMT-1660
- Mersana Therapeutics: ‘Positive’ results from Phase 1 emiltatug ledadotin trial
- Mersana Therapeutics transferred with Buy rating at Citi
- Mersana Therapeutics Reports Q3 2024 Financial Results